SHIRONG ZHANG

SHIRONG ZHANG


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
WWWenwen Wang
Wenwen Wang
JZJingjing Zhang
Jingjing Zhang
YWYuqing Wang
Yuqing Wang
YXYasi Xu
Yasi Xu
SZSHIRONG ZHANG
SHIRONG ZHANG
• Aberrant expression of CSPP1 serves as a diagnostic and prognostic biomarker in multiple cancers. • Phosphorylation of CSPP1 at specific sites may regulate its activity. • Functional enrichment indicates CSPP1 is potentially associated with ferroptosis and TME in LGG. • CSPP1 dysregulates ferroptosis in LGG and other cancer types. • CSPP1-associated tumors are infiltrated in different TMEs, improving ICB therapeutic efficacy in specific cancers.

1 January 2022 in Cancer Letters
Verified
Journal Article
Open access
JZJingjing Zhang
Jingjing Zhang
QWQiong Wu
Qiong Wu
LZLucheng Zhu
Lucheng Zhu
SXShujun Xie
Shujun Xie
LTLinglan Tu
Linglan Tu
SZSHIRONG ZHANG
SHIRONG ZHANG
Although the DNA damage response (DDR) is associated with the radioresistance characteristics of lung cancer cells, the specific regulators and underlying mechanisms of the DDR are unclear. Here, we identified the serine proteinase inhibitor clade E member 2 (SERPINE2) as a modulator of radiosensitivity and the DDR in lung cancer. Cells exhibiting radioresistance after ionizing radiation show upregulation of SERPINE2, and SERPINE2 knockdown improves tumor radiosensitivity in vitro and in vivo. Functionally, SERPINE2 deficiency causes a reduction in homologous recombination repair, rapid recovery of cell cycle checkpoints, and suppression of migration and invasion. Mechanistically, SERPINE2 knockdown inhibits the accumulation of p-ATM and the downstream repair protein RAD51 during DNA repair, and RAD51 can restore DNA damage and radioresistance phenotypes in lung cancer cells. Furthermore, SERPINE2 can directly interact with MRE11 and ATM to facilitate its phosphorylation in HR-mediated DSB repair. In addition, high SERPINE2 expression correlates with dismal prognosis in lung adenocarcinoma patients, and a high serum SERPINE2 concentration predicts a poor response to radiotherapy in non-small cell lung cancer patients. In summary, these findings indicate a novel regulatory mechanism by which SERPINE2 modulates the DDR and radioresistance in lung cancer.

6 November 2020 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
YZYan-Yan Zhao
Yan-Yan Zhao
JJJing Jia
Jing Jia
JZJing-Jing Zhang
Jing-Jing Zhang
YXYan-Ping Xun
Yan-Ping Xun
SXShu-Jun Xie
Shu-Jun Xie
SZSHIRONG ZHANG
SHIRONG ZHANG

16 March 2023 in Thoracic Cancer
Verified
Journal Article
Open access
CXChun-wei Xu
Chun-wei Xu
Yongchang ZhangYongchang Zhang
Yongchang Zhang
WWWenxian Wang
Wenxian Wang
QWQian Wang
Qian Wang
ZLZiming Li
Ziming Li
WZWen-Zhao Zhong
Wen-Zhao Zhong
Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for less than 1% of all tumors. The incidence of TETs is about 3.93/10000 in China, slightly higher than that of European and American countries. For resectable TETs, complete surgical resection is recommended. Radiotherapy or chemotherapy may be used as postoperative adjuvant treatment. Treatment for advanced, unresectable TETs consist mainly of radiotherapy and chemotherapy, but there is a lack of standard first‐ and second‐line treatment regimens. Recently, targeted therapies and immune checkpoint inhibitors have shown promising outcomes in TETs. Based on the currently available clinical evidences and the opinions of the national experts, the Thymic Oncology Group of Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) established this Chinese expert consensus on the clinical diagnosis and treatment of TETs, covering the epidemiology, diagnosis, treatment, prognosis and follow‐up of TETs.

7 August 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SZSHIRONG ZHANG
SHIRONG ZHANG
XZXiaochen Zhang
Xiaochen Zhang
WLWei Lei
Wei Lei
JLJiafeng Liang
Jiafeng Liang
YXYasi Xu
Yasi Xu
SMSheng Lin Ma
Sheng Lin Ma
Lung cancer is the second most common cancer with an extremely poor overall survival rate. Post-transcriptional regulation of gene expression play many important roles in human cancer, and one of the potential mechanisms underlying this is alternative mRNA maturation at its 3′ untranslated regions (3′-UTRs). Cancer tissues and paired adjacent normal lung tissues from 26 patients diagnosed with non-small cell lung cancer (NSCLC) were analyzed by in vitro transcription-sequencing alternative polyadenylation sites (IVT-SAPAS). 41,773,101 reads in average were obtained from each paired sample. A potential regulation of Cleavage Stimulation Factor Subunit 2 (CSTF2) on 3′UTR length of genes was tested in H460 cells. 1439 (10.26%) genes showed up-regulated expression and 1364 (9.72%) genes showed down-regulated expression in lung cancer tissue versus normal lung tissue, and shorten 3′UTR in cancer tissue was detected in cancer tissues collected from 96.2% (25/26) patients, indicating lung cancer tend to have shortened 3′UTRs of these identified genes. KEGG analysis showed 1855 genes with shorten 3′UTR were enriched in mTOR signaling, ubiquitin mediated proteolysis and RNA degradation. Knocking down CSTF2 expression in H460 cells results in 3′UTR elongation of genes that was identified to be with shortened length in cancer tissues. Alternative polyadenylation (APA) site-switching of 3′UTRs is prevalent in NSCLC, and CSTF2 may serve as an oncogene regulates the 3′UTR length of cancer related genes in NSCLC.

17 July 2023 in Thoracic Cancer
Verified
Journal Article
Open access
QWQian Wang
Qian Wang
CXChun-wei Xu
Chun-wei Xu
WWWenxian Wang
Wenxian Wang
Yongchang ZhangYongchang Zhang
Yongchang Zhang
ZLZiming Li
Ziming Li
WFWenfeng Fang
Wenfeng Fang
Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high‐risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow‐up.